[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Earnings Preview: What To Expect From Moderna’s Report

Valued at a market cap of $23.7 billion, Moderna, Inc. (MRNA) is a biotechnology company focused on developing messenger RNA (mRNA)-based medicines and vaccines. Headquartered in Cambridge, Massachusetts, Moderna aims to use mRNA technology to instruct the body's cells to produce proteins that can prevent or treat diseases.

The biotech titan is expected to announce its fiscal Q2 earnings for 2026 before the market opens on Friday, Jul. 31. Ahead of this event, analysts expect this biotechnology company to report a loss of $1.97 per share, an improvement of 7.5% from a loss of $2.13 per share in the year-ago...

Fundamentals

See More
  • Market Capitalization, $K 21,454,220
  • Shares Outstanding, K 396,786
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,412 M
  • EBITDA $ -3,264 M
  • 60-Month Beta 0.94
  • Price/Sales 11.64
  • Price/Cash Flow N/A
  • Price/Book 3.05

Options Overview Details

View History
  • Implied Volatility 89.88% (+0.30%)
  • Historical Volatility 87.02%
  • IV Percentile 92%
  • IV Rank 72.72%
  • IV High 103.33% on 11/03/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 5) 5.21 (9.64%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 36,723
  • Volume Avg (30-Day) 52,649
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 589,444
  • Open Int (30-Day) 581,914
  • Expected Range 48.86 to 59.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.97
  • Number of Estimates 8
  • High Estimate $-1.32
  • Low Estimate $-2.35
  • Prior Year $-2.13
  • Growth Rate Est. (year over year) +7.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.85 +0.41%
on 07/24/26
85.60 -36.83%
on 07/06/26
-6.35 (-10.51%)
since 06/24/26
3-Month
43.68 +23.79%
on 05/01/26
85.60 -36.83%
on 07/06/26
+3.34 (+6.58%)
since 04/24/26
52-Week
22.28 +142.68%
on 11/21/25
85.60 -36.83%
on 07/06/26
+20.06 (+58.98%)
since 07/24/25

Most Recent Stories

More News
Earnings Preview: What To Expect From Moderna’s Report

Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.

XLV : 162.57 (+0.70%)
$SPX : 7,411.98 (+0.05%)
MRNA : 54.07 (-5.17%)
14 S&P 500 Stocks Are Up Over 100% in 2026. Why Micron Is My Favorite for the Rest of the Year.

Among the 14 S&P 500 stocks that have surged more than 100% so far this year, Micron stands out as my top pick.

AMAT : 536.25 (-4.72%)
GOOG : 319.09 (+0.24%)
GOOGL : 319.74 (+0.65%)
META : 595.19 (-1.80%)
SNDK : 1,436.56 (-10.79%)
$SPX : 7,411.98 (+0.05%)
MU : 920.95 (-6.99%)
LITE : 762.99 (-8.47%)
DVA : 235.44 (+0.50%)
MSFT : 381.70 (+0.03%)
FTNT : 152.37 (+0.55%)
STX : 851.69 (-6.75%)
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?

Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?

MRNA : 54.07 (-5.17%)
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer...

MRNA : 54.07 (-5.17%)
Why Moderna (MRNA) Stock Is Trading Up Today

Why Moderna (MRNA) Stock Is Trading Up Today

MRNA : 54.07 (-5.17%)
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its...

MRNA : 54.07 (-5.17%)
Moderna Appoints Michael McDonnell to Board of Directors

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience

MRNA : 54.07 (-5.17%)
MarketBeat Week in Review – 06/29 - 07/03

MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season.

NFLX : 70.09 (+1.74%)
META : 595.19 (-1.80%)
AVGO : 381.92 (-2.69%)
SNDK : 1,436.56 (-10.79%)
RKLB : 63.91 (-8.69%)
MDA : 29.57 (-4.24%)
NEE : 89.78 (-0.01%)
HSY : 174.30 (+1.25%)
QSR : 72.47 (+0.12%)
COST : 935.03 (+0.97%)
TSLA : 313.03 (-2.08%)
SPCX : 115.07 (-2.68%)
3 Cash-Heavy Stocks with Warning Signs

3 Cash-Heavy Stocks with Warning Signs

FVRR : 10.46 (+1.65%)
PEGA : 26.82 (+3.11%)
MRNA : 54.07 (-5.17%)
Trump’s Newly Disclosed Moderna Trades Preceded FDA Advisory Panel’s Unanimous Backing of mRNA Flu Vaccine

President Donald Trump’s stock transaction filings reveal multiple purchases of Moderna ($MRNA) during March 2026, followed by a partial sale on May 18. Since those trades, the FDA's Vaccines and Related...

MRNA : 54.07 (-5.17%)
PFE : 24.54 (-0.16%)
GSK : 51.35 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 60.01
2nd Resistance Point 58.74
1st Resistance Point 56.40
Last Price 54.07
1st Support Level 52.79
2nd Support Level 51.52
3rd Support Level 49.18

See More

52-Week High 85.60
Fibonacci 61.8% 61.41
Last Price 54.07
Fibonacci 50% 53.94
Fibonacci 38.2% 46.47
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.